Page 63 - 台灣肝癌醫學冬季會手冊-1222-V3_Neat

Abstract

Background: Nivolumab, an immune checkpoint inhibitor, is approved to treat

sorafenib-experienced patients with hepatocellular carcinoma (HCC). Whether

concurrent radiation therapy can increase the response rate of Nivolumab remains

unclear.

Method: A total of 22 patients who received nivolumab treatment between January

2018 and May 2020 at Taipei Tzu-Chi Hospital were included. Concurrent nivolumab

plus radiation therapy was defined as radiation therapy concurrently or less than one

month before nivolumab treatment. AFP decline is defined as 10 % reduction of AFP

after 2 months of Nivolumab treatment.

Result: 22 HCC patients (20 males; median age 67; range 39-89 year-old) had

received at least two cycle of Nivolumab. Median follow‐up duration of all patients

was 13.77 (range, 1.77‐25.2) months. All patients were cirrhotic (18 with child A and

4 with Child B). The BCLC stage was B in 8 patients and C in 14 patients (Table 1). 8

patients had concurrent Nivolumab and radiation therapy. During the follow‐up